Yan Wang

机构：Harbin Medical University, Sun Yat-sen University, Capital Medical University, Peking University, Beijing Jishuitan Hospital, National Institute of Dental and Craniofacial Research, Shaanxi Provincial People's Hospital, Fudan University Shanghai Cancer Center, Peking University Cancer Hospital, First Affiliated Hospital of Guangzhou Medical University, Shanghai University of Traditional Chinese Medicine, Third Affiliated Hospital of Harbin Medical University, Guang’anmen Hospital, Sun Yat-sen University Cancer Center, Ministry of Education, Shuguang Hospital, Guangzhou Medical University · ORCID：0000-0003-4862-3912

发表论文 66 篇 · 总被引 299 次 · h-index 9

代表论文

• Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study (2024 · Nature Communications · 被引 26)
• Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study (2024 · EBioMedicine · 被引 10)
• Decoding the neuroimmune axis in colorectal cancer: From neural circuitry to therapeutic innovation (2025 · Cytokine & Growth Factor Reviews · 被引 7)
• Glycoproteomics analysis of colorectal cancer reveals differential alterations of glycoproteins and glycans (2025 · Analytical and Bioanalytical Chemistry · 被引 6)
• Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study. (2025 · Journal of Clinical Oncology · 被引 6)
• 1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca) (2023 · Annals of Oncology · 被引 6)